Alzheimer's disease, a progressive brain disorder, affects millions and is projected to increase. While age and genetics play ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients ...

Researchers now have a powerful new way to understand the types of brain cells that are affected in neurodegenerative diseases and to uncover connections between conditions such as Parkinson's, ...

We appreciate the opportunity to address the comments by Yangfan Cheng and colleagues, and Sebastian Walsh and colleagues regarding our Article on long-term gantenerumab treatment in dominantly ...

We read with great interest the Article by Randall J Bateman and colleagues investigating long-term gantenerumab treatment in dominantly inherited Alzheimer's disease.1 This important work provides ...

California is on the cusp of a demographic shift, with the number of people 65 and older skyrocketing by 59% over the next 15 ...

The Alzheimer's Association of Greater Kentucky and Southern Indiana held the kickoff party on Wednesday for its Walk to End ...

The Broward Sheriff’s Office Missing Persons unit asked for the public’s help Wednesday in locating a 76-year-old man who ...

Single-cell genomics has unlocked new frontiers in understanding cell types in the brain and targeting them with therapies.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

A free database of biomarker information on neurodegenerative diseases was released with backing from Bill Gates, Johnson & ...

Living with Alzheimer’s disease can be both challenging and frightening. However, stories of resilience and hope can inspire ...